(VIANEWS) – Shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) dropped by a staggering 27.58% in 21 sessions from $15.92 at 2023-04-28, to $11.53 at 15:54 EST on Tuesday, after four consecutive sessions in a row of losses. NASDAQ is rising 0.47% to $13,036.42, after two successive sessions in a row of gains.
Catalyst Pharmaceuticals’s last close was $11.50, 47.99% below its 52-week high of $22.11.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.88.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 13.1. Meaning, the purchaser of the share is investing $13.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.89%.
Moving Average
Catalyst Pharmaceuticals’s value is way under its 50-day moving average of $15.76 and way below its 200-day moving average of $15.48.
Revenue Growth
Year-on-year quarterly revenue growth grew by 98.1%, now sitting on 256.48M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 40% and 50%, respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Catalyst Pharmaceuticals’s stock is considered to be overbought (>=80).
More news about Catalyst Pharmaceuticals (CPRX).
